| |
| |
|
| Insider
Information: |
Breitmeyer James B |
| Relationship: |
Chief Executive Office... |
| City: |
|
| State: |
|
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
3 |
|
| Direct
Shares |
453,034 |
|
|
Indirect Shares
|
212,703 |
|
|
| Direct
Value |
$151,783 |
|
|
|
Indirect Value
|
$72,872 |
|
|
| Total
Shares |
665,737 |
|
|
| Total
Value |
$224,655 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
3
|
0
|
|
Stock
price went up :
|
2
|
0
|
| Stock
price went down : |
1
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
2.0
|
0.0
|
| Percentage
Gain/Loss : |
 43.5%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Cadence Pharmaceuticals Inc |
CADX |
EVP, CMO |
2011-11-03 |
10,000 |
2009-09-01 |
0 |
Premium* |
|
|
Zogenix, Inc. |
ZGNX |
Director |
2022-03-07 |
0 |
|
0 |
Premium* |
|
|
Oncternal Therapeutics Inc |
ONCT |
Chief Executive Office... |
2024-01-03 |
443,034 |
2024-01-03 |
212,703 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
25 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 1
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| ONCT |
Oncternal Therapeutics In... |
Chief Executive Officer |
• • – |
2024-01-03 |
4 |
D |
$0.50 |
$2,225 |
I/I |
(4,485) |
15,426 |
0 |
- |
|
| ONCT |
Oncternal Therapeutics In... |
Chief Executive Officer |
• • – |
2024-01-03 |
4 |
D |
$0.50 |
$25,279 |
D/D |
(50,955) |
443,034 |
0 |
- |
|
| ONCT |
Oncternal Therapeutics In... |
Chief Executive Officer |
• • – |
2023-07-03 |
4 |
D |
$0.36 |
$1,443 |
I/I |
(4,007) |
19,911 |
0 |
- |
|
| ONCT |
Oncternal Therapeutics In... |
Chief Executive Officer |
• • – |
2023-07-03 |
4 |
D |
$0.36 |
$17,277 |
D/D |
(47,992) |
493,989 |
0 |
- |
|
| ONCT |
Oncternal Therapeutics In... |
Chief Executive Officer |
• • – |
2023-04-14 |
4 |
B |
$0.29 |
$14,930 |
I/I |
50,000 |
196,544 |
2.58 |
% |
|
| ONCT |
Oncternal Therapeutics In... |
Chief Executive Officer |
• • – |
2023-04-13 |
4 |
B |
$0.29 |
$29,000 |
I/I |
100,000 |
146,544 |
2.66 |
% |
|
| ONCT |
Oncternal Therapeutics In... |
Chief Executive Officer |
• • – |
2023-01-03 |
4 |
D |
$1.02 |
$28,349 |
D/D |
(27,793) |
541,981 |
0 |
- |
|
| ONCT |
Oncternal Therapeutics In... |
Chief Executive Officer |
• • – |
2023-01-03 |
4 |
D |
$1.02 |
$1,352 |
I/I |
(1,325) |
23,918 |
0 |
- |
|
| ONCT |
Oncternal Therapeutics In... |
Chief Executive Officer |
• • – |
2022-07-28 |
4 |
A |
$0.00 |
$0 |
I/I |
18,750 |
25,243 |
0 |
- |
|
| ONCT |
Oncternal Therapeutics In... |
Chief Executive Officer |
• • – |
2022-07-28 |
4 |
A |
$0.00 |
$0 |
D/D |
185,625 |
569,774 |
0 |
- |
|
| ZGNX |
Zogenix, Inc. |
Director |
– • – |
2022-03-07 |
4 |
D |
$0.00 |
$0 |
D/D |
(1,250) |
0 |
0 |
- |
|
| ONCT |
Oncternal Therapeutics In... |
Chief Executive Officer |
• • – |
2022-01-27 |
4 |
B |
$1.68 |
$42,080 |
I/I |
25,000 |
46,544 |
2.66 |
% |
|
| ONCT |
Oncternal Therapeutics In... |
Chief Executive Officer |
• • – |
2022-01-03 |
4 |
A |
$0.00 |
$0 |
I/I |
6,793 |
6,793 |
0 |
- |
|
| ONCT |
Oncternal Therapeutics In... |
Chief Executive Officer |
• • – |
2022-01-03 |
4 |
A |
$0.00 |
$0 |
D/D |
128,557 |
384,149 |
0 |
- |
|
| ZGNX |
Zogenix, Inc. |
Director |
– • – |
2019-12-16 |
4 |
OE |
$8.99 |
$44,950 |
D/D |
5,000 |
6,250 |
0 |
- |
|
| ZGNX |
Zogenix, Inc. |
Director |
– • – |
2019-12-16 |
4 |
AS |
$50.00 |
$250,000 |
D/D |
(5,000) |
1,250 |
0 |
- |
|
| ONCT |
Oncternal Therapeutics In... |
President, CEO |
• • – |
2019-06-07 |
4 |
A |
$0.00 |
$0 |
I/I |
22,277 |
21,544 |
0 |
- |
|
| ONCT |
Oncternal Therapeutics In... |
President, CEO |
• • – |
2019-06-07 |
4 |
A |
$0.00 |
$0 |
D/D |
255,591 |
255,591 |
0 |
- |
|
| ZGNX |
Zogenix, Inc. |
Director |
– • – |
2014-03-25 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
10,000 |
|
- |
|
| CADX |
Cadence Pharmaceuticals I... |
EVP, CMO |
• – – |
2011-11-03 |
4 |
AS |
$5.70 |
$71,304 |
D/D |
(12,500) |
10,000 |
0 |
- |
|
| CADX |
Cadence Pharmaceuticals I... |
EVP, CMO |
• – – |
2011-11-02 |
4 |
OE |
$0.00 |
$0 |
D/D |
12,500 |
22,500 |
0 |
- |
|
| CADX |
Cadence Pharmaceuticals I... |
EVP, CMO |
• – – |
2011-07-11 |
4 |
AS |
$8.99 |
$26,970 |
D/D |
(3,000) |
10,000 |
0 |
- |
|
| CADX |
Cadence Pharmaceuticals I... |
EVP, CMO |
• – – |
2011-07-11 |
4 |
OE |
$3.20 |
$9,600 |
D/D |
3,000 |
13,000 |
0 |
- |
|
| CADX |
Cadence Pharmaceuticals I... |
EVP, CMO |
• – – |
2011-05-02 |
4 |
AS |
$8.35 |
$100,163 |
D/D |
(12,000) |
10,000 |
0 |
- |
|
| CADX |
Cadence Pharmaceuticals I... |
EVP, CMO |
• – – |
2011-05-02 |
4 |
OE |
$3.20 |
$38,400 |
D/D |
12,000 |
22,000 |
0 |
- |
|
25 Records found
|
1
|
Page 1 of 1 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
